En observasjonsstudie etter markedsføring som bruker kommersielt godkjente Biosense Webster (BWI) medisinske enheter for behandling av deltakere med hjertearytmier (SECURE)
En observasjonsstudie etter markedsføring for evaluering av pågående sikkerhet og effektivitet av kateterkartlegging og ablasjon ved bruk av kommersielt godkjente BWI medisinske enheter for behandling av pasienter med hjertearytmier
The purpose of this study is to prospectively collect clinical data evaluating the ongoing safety and performance during routine-use standard cardiac arrhythmia mapping and/or ablation procedures while using commercial Biosense Webster Inc. (BWI) medical devices. Data generated from the study will be used to confirm safety and performance of BWI medical devices in the marketed phase and to expand the body of evidence on the use of these devices and techniques in treatment of cardiac arrhythmias.
Studieoversikt
Status
Status
Forhold
Forhold
Intervensjon / Behandling
Intervensjon / Behandling
Studietype
Studietype
Registrering (Antatt)
Registrering
Kontakter og plasseringer
Studiekontakt
Studiekontakt
- Navn: Nathalie Macours
- Telefonnummer: +32 479 97 05 05
- E-post: nmacours1@its.jnj.com
Studer Kontakt Backup
- Navn: Liesbeth Gorissen
- E-post: LGORISSE@ITS.JNJ.com
Studiesteder
-
-
-
Aalst, Belgia, 9300
- Rekruttering
- OLV Aalst
-
Bruges, Belgia, 8000
- Rekruttering
- AZ Sint-Jan Brugge
-
Brussels, Belgia, 1000
- Rekruttering
- CHU Saint-Pierre
-
Edegem, Belgia, 2650
- Rekruttering
- UZ Antwerp
-
Ghent, Belgia, 9000
- Rekruttering
- Maria Middelares
-
Hasselt, Belgia, 3500
- Rekruttering
- Jessa Hospital
-
Jette, Belgia, 1090
- Rekruttering
- UZ Brussels
-
La Louvière, Belgia, 7100
- Rekruttering
- ASBL CHU HELORA Hôpital de La Louvière site Jolimont
-
-
-
-
-
Aarhus, Danmark, 8200
- Rekruttering
- Aarhus University Hospital
-
Copenhagen, Danmark, 2100
- Rekruttering
- Rigshospitalet
-
-
-
-
-
Clermont-Ferrand, Frankrike, 63000
- Rekruttering
- CHU de Clermont-Ferrand
-
Lyon, Frankrike, 69002
- Rekruttering
- Les Hospices Civils de Lyon
-
Marseille, Frankrike, 13285
- Rekruttering
- Hôpital Saint Joseph de Marseille
-
Paris, Frankrike, 75674
- Rekruttering
- Institut Mutualiste Montsouris
-
Rennes, Frankrike, 35033
- Rekruttering
- CHU de Rennes
-
Strasbourg, Frankrike, 67000
- Rekruttering
- Les Hôpitaux Universitaires de Strasbourg
-
Talence, Frankrike, 33404
- Rekruttering
- Centre Hospitalier Universitaire de Bordeaux
-
-
-
-
-
Dublin, Irland, D07 WKW8
- Rekruttering
- Mater Private Heart and Vascular Centre
-
-
-
-
-
Jerusalem, Israel, 9103102
- Rekruttering
- Shaare Zedek Medical Center
-
Tel Aviv, Israel, 6423906
- Fullført
- Tel Aviv Sourasky Medical Center
-
-
-
-
-
Acquaviva delle Fonti, Italia, 70021
- Rekruttering
- Ospedale Generale Regionale "F. Miulli"
-
Ancona, Italia, 60126
- Rekruttering
- A.O. Universitaria Delle Marche
-
Milan, Italia, 20097
- Rekruttering
- IRCCS Policlinico San Donato
-
Naples, Italia, 80122
- Rekruttering
- Clinica Mediterranea
-
-
-
-
-
Maastricht, Nederland, 6229 EV
- Rekruttering
- Clinical Trial Center Maastricht
-
Rotterdam, Nederland, 3015 GD
- Rekruttering
- Erasmus University Medical Center
-
-
-
-
-
Bergen, Norge, 5021
- Rekruttering
- Haukeland University Hospital
-
-
-
-
-
Carnaxide, Portugal, 2790-134
- Rekruttering
- Hospital de Santa Cruz
-
-
-
-
-
Leicester, Storbritannia, LE3 9QP
- Rekruttering
- Glenfield Hospital
-
London, Storbritannia, SW3 6NP
- Rekruttering
- Royal Brompton Hospital
-
London, Storbritannia, SW17 0QT
- Rekruttering
- St George's Hospital
-
London, Storbritannia, EC1A 7BE
- Fullført
- St. Bartholomew's Hospital
-
-
-
-
-
Bern, Sveits, 03010
- Rekruttering
- INSELSPITAL Universitätsspital Bern
-
-
-
-
-
Gothenburg, Sverige, 413 45
- Rekruttering
- Sahlgrenska University Hospital
-
-
-
-
-
Bad Neustadt an der Saale, Tyskland, 97616
- Rekruttering
- Rhön-Klinikum Campus Bad Neustadt
-
Bad Oeynhausen, Tyskland, 3245
- Rekruttering
- Herz- und Diabeteszentrum NRW, University Hospital of the Ruhr University Bochum
-
Bad Segeberg, Tyskland, 23795
- Rekruttering
- Segeberger Kliniken
-
Bautzen, Tyskland, 02625
- Rekruttering
- Oberlausitz-Kliniken
-
Essen, Tyskland, 45131
- Rekruttering
- Alfried Krupp Hospital
-
Frankfurt, Tyskland, 60431
- Fullført
- Cardioangiologisches Centrum Bethanien (CCB)
-
Giessen, Tyskland, 35390
- Rekruttering
- Justus-Liebig-University Giessen
-
Hamburg, Tyskland, 22763
- Rekruttering
- Asklepios Klinik Altona
-
Munich, Tyskland, 80636
- Rekruttering
- German Heart Centre Munich
-
-
-
-
-
Budapest, Ungarn, H-1085
- Rekruttering
- Semmelweis University
-
-
-
-
-
Graz, Østerrike, 8010
- Rekruttering
- Medical University of Graz
-
Linz, Østerrike, 4020
- Rekruttering
- Ordensklinikum Linz GMBH
-
Wiener Neustadt, Østerrike, 2700
- Rekruttering
- Universitätsklinikum Wiener Neustadt
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Barn
- Voksen
- Eldre voksen
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Study population consists of participants diagnosed with cardiac arrhythmias who are scheduled to undergo an ablation procedure for management of their arrhythmia with a per-protocol defined Biosense Webster Inc (BWI) therapeutic catheter.
Beskrivelse
Inclusion criteria
- Diagnosed with paroxysmal or persistent Atrial Fibrillation (AF) or supraventricular tachycardia (SVT) or ventricular tachycardia (VT) and scheduled to undergo an ablation procedure for management of their arrhythmia with a per-protocol defined BW therapeutic catheter
- Able and willing to comply with all pre, post and follow-up testing and requirements as per hospital standard of care
- Signed patient informed consent form (ICF) as applicable per local regulation
Exclusion criteria:
- Currently participating in an interventional (drug, device, biologic) clinical trial
- Life expectancy of less than 12-months
- Presenting any contraindication for the use of BWI commercially approved medical devices, as indicated in the respective user manuals
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Observasjonsmodeller: COHORT
- Tidsperspektiver: PROSPECTIVE
Antall grupper / kohorter
Kohorter og intervensjoner
Gruppe / KohortGruppe / Kohort |
Intervensjon / BehandlingIntervensjon / Behandling |
|---|---|
|
Participants Diagnosed with Cardiac Arrhythmias
Patients diagnosed with cardiac arrhythmias who are scheduled to undergo an ablation procedure in routine clinical practice for management of their arrhythmia with a BWI therapeutic catheter/Varipulse Catheter/ Dual Energy Thermocool Smarttouch surround flow (SF) catheter will be observed. |
Participants will be treated with commercially approved BWI medical devices following routine clinical practice. No specific intervention will be observed for this study. Participants treated with Varipulse Catheter in the main study will be part of the VARIPURE sub-study. No specific intervention will be observed for this study. Participants treated with the Dual Energy THERMOCOOL SMARTTOUCH SF Catheter in the main study will be part of the DUACURE sub-study. No specific intervention will be observed for this study. |
Hva måler studien?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Number of Participants with Primary Adverse Events (PAEs) Related to Device in Scope and/or Study Procedure Within 7 Days of the Initial Study Procedure
Tidsramme: Up to 7 Days
|
PAEs in participants with Atrial Fibrillation (AF) and for SupraVentricular Tachycardia (SVT) includes device or procedure related death, atrio-esophageal fistula/ esophageal perforation , severe pulmonary vein stenosis, cardiac tamponade/perforation, thromboembolism, pericarditis, stroke/cerebrovascular accident, transient ischemic attack, phrenic nerve paralysis (permanent), myocardial infarction, major vascular access complication/bleeding, heart block; PAEs in participants with Ventricular Tachycardia (VT) includes device or procedure related death, cardiac tamponade/perforation, thromboembolism, pericarditis, stroke/cerebrovascular accident, transient ischemic attack, phrenic nerve paralysis (permanent), myocardial infarction, major vascular access complication/bleeding, heart block, aggravation or new onset heart failure, coronary artery injury, aortic dissection and valve injury. |
Up to 7 Days
|
|
AF: Number of Participants with Isolation of all Targeted Pulmonary Veins
Tidsramme: Up to 7 Days
|
Number of Participants with isolation (entrance block confirmation) of all targeted pulmonary veins will be reported. |
Up to 7 Days
|
|
SVT (Sinus Nodal Re-entrant Tachycardia, Focal AT, Multifocal AT, AVNRT, Non Re-entrant Junctional Tachycardias): Number of Participants with Non-inducibility of the Targeted Tachycardia at end of Procedure
Tidsramme: Up to 7 Days
|
Number of participants with sinus nodal re-entrant tachycardia, focal atrial tachycardia (AT) multifocal AT, atrioventricular nodal reentry tachycardia (AVNRT), non re-entrant junctional tachycardias with non-inducibility of the targeted tachycardia at end of procedure will be reported. |
Up to 7 Days
|
|
SVT (MRAT): Number of Participants with Complete Bidirectional Conduction Block Across the Ablation Line
Tidsramme: Up to 7 Days
|
Number of participants with Macro Re-entrant Atrial Tachycardia (MRAT) with complete bidirectional conduction block across the ablation line will be reported. |
Up to 7 Days
|
|
SVT (AVRT): Number of Participants with Complete Block of Accessory Pathway
Tidsramme: Up to 7 Days
|
Number of participants with atrioventricular reentry tachycardia (AVRT) with complete block of accessory pathway will be reported. |
Up to 7 Days
|
|
VT (Ischemic or Non-ischemic): Number of Participants with Non-inducibility of the Targeted VT at end of Procedure
Tidsramme: Up to 7 days
|
Number of participants with non-inducibility of the targeted ischemic or non-ischemic VT at end of procedure will be reported. |
Up to 7 days
|
|
VT (Idiopathic): Number of Participants with Elimination of Clinically Relevant VT
Tidsramme: Up to 7 days
|
Number of participants with elimination of clinically relevant idiopathic VT will be reported. Clinically relevant: any spontaneous VT or any induced VT. |
Up to 7 days
|
|
VT (Idiopathic): Number of Participants with Elimination of Clinically Relevant Premature Ventricular Contraction (PVCs)
Tidsramme: Up to 7 days
|
Number of participants with elimination of clinically relevant idiopathic PVCs will be reported. Clinically relevant: any spontaneous PVC or any induced PVC; prior to treatment, PVCs would be deemed clinically relevant if they are present greater than (>) 20 percent (%) of daily heartbeat. |
Up to 7 days
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Number of Participants with Device and/or Procedure-Related Serious Adverse Events (Serious Adverse Device Effects [SADEs])
Tidsramme: Up to 365 Days
|
Number of participants with device and/or procedure-related Serious Adverse Events (SADEs) within 7 days (early-onset), >7-30 days (peri-procedural) and >30 days (late onset) following the initial study procedure will be reported. |
Up to 365 Days
|
|
Number of Participants with Device and/or Procedure-Related Non-Serious Adverse Events (Non-Serious Adverse Device Effects [ADEs])
Tidsramme: Up to 365 Days
|
Number of participants with device and/or procedure-related non-serious adverse events (Non-serious ADEs) within 7 days (early-onset), >7-30 days (peri-procedural) and >30 days (Late Onset) following the initial study procedure will be reported. |
Up to 365 Days
|
|
AF: Number of Participants with Acute Reconnection Among all Targeted Pulmonary Veins (PVs)
Tidsramme: Up to 7 Days
|
Number of participants with Acute reconnection among all targeted PVs will be reported. |
Up to 7 Days
|
|
SVT (MRAT): Number of Participants with Non-inducibility of the Targeted Tachycardia at end of Procedure
Tidsramme: Up to 7 Days
|
Number of participants with MRAT with non-inducibility of the targeted tachycardia at end of procedure will be reported. |
Up to 7 Days
|
|
SVT (AVNRT): Number of Participants with Elimination or Modification of Slow Pathway Conduction
Tidsramme: Up to 7 Days
|
Number of participants with AVNRT with elimination or modification of slow pathway conduction will be reported. |
Up to 7 Days
|
|
VT (Ischemic or Non-ischemic): Number of Participants with Non-inducibility of any VT at end of Procedure
Tidsramme: Up to 7 Days
|
Number of participants with non-inducibility of any VT (Ischemic or Non-ischemic) at end of procedure will be reported. |
Up to 7 Days
|
|
VT (Ischemic or Non-ischemic): Number of Participants with Elimination of all Targeted Late Potentials and Local Abnormal Ventricular Activation (LAVAs) at end of Procedure
Tidsramme: Up to 7 Days
|
Number of participants with elimination of all targeted late potentials and local abnormal ventricular activation (LAVAs) at end of procedure will be reported. |
Up to 7 Days
|
|
AF: Number of Participants with Freedom From Documented (Symptomatic and Asymptomatic) AF, AT, Atrial Flutter (AFL) Episodes
Tidsramme: From Day 91 to Day 365 (post-blanking)
|
Number of participants with freedom from documented (symptomatic and asymptomatic) AF, AT, AFL episodes (episodes greater than or equal to [>=] 30 seconds) post-blanking will be reported. |
From Day 91 to Day 365 (post-blanking)
|
|
AF: Number of Participants with Freedom From Documented Symptomatic AF, AT, AFL Episodes
Tidsramme: From Day 91 to Day 365 (post-blanking)
|
Number of participants with freedom from documented symptomatic AF, AT, AFL episodes (episodes >= 30 seconds) post-blanking will be reported. |
From Day 91 to Day 365 (post-blanking)
|
|
AF: Number of Participants with Repeated Ablation
Tidsramme: From Day 91 to Day 365 (post-blanking)
|
Number of participants with repeated ablation post-blanking will be reported. |
From Day 91 to Day 365 (post-blanking)
|
|
AF: Number of Participants with Repeated Ablation with Pulmonary Vein (PV) Reconnection
Tidsramme: From Day 91 to Day 365 (post-blanking)
|
Number of participants with repeated ablation with PV reconnection post blanking will be reported. |
From Day 91 to Day 365 (post-blanking)
|
|
SVT: Number of Participants with Freedom From Documented Arrhythmia of the Primary SVT
Tidsramme: From Day 1 to Day 365
|
Number of participants with freedom from documented arrhythmia of the primary SVT (episodes >=30 seconds) will be reported. |
From Day 1 to Day 365
|
|
SVT: Number of Participants with Freedom From Documented Arrhythmia of new SVT, not Targeted During Index Procedure
Tidsramme: From Day 1 to Day 365
|
Number of participants with freedom from documented arrhythmia of new SVT, not targeted during index procedure will be reported. |
From Day 1 to Day 365
|
|
SVT: Number of Participants with Repeated Ablation
Tidsramme: From Day 1 to Day 365
|
Number of participants with repeated ablation will be reported. |
From Day 1 to Day 365
|
|
VT: Number of Participants with Freedom From Documented Arrhythmia of the Clinically Relevant/Targeted VT
Tidsramme: From Day 1 to Day 365
|
Number of participants with freedom from documented arrhythmia of the clinically relevant /targeted VT (episodes >=30 seconds) will be reported. |
From Day 1 to Day 365
|
|
VT: Number of Participants with Freedom From Documented Arrhythmia of new VT, not Targeted During Index Procedure
Tidsramme: From Day 1 to Day 365
|
Number of participants with freedom from documented arrhythmia of new VT, not targeted during index procedure will be reported. |
From Day 1 to Day 365
|
|
VT: Number of Participants with Repeated Ablation
Tidsramme: From Day 1 to Day 365
|
Number of participants with repeated ablation will be reported. |
From Day 1 to Day 365
|
|
VT: Number of Participants with All Cause and Cardiac Mortality
Tidsramme: Up to Day 365
|
Number of participants with all cause and cardiac mortality will be reported. |
Up to Day 365
|
|
VT: Number of Participants with Heart Failure Hospitalization
Tidsramme: Up to Day 365
|
Number of participants with heart failure hospitalization will be reported. |
Up to Day 365
|
Andre resultatmål
Andre resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
VARIPURE sub-study: Number of Participants With Coronary Spasm During Ablation
Tidsramme: Up to Day 365
|
Ablation procedures using the varipulse medical device will be performed according to the hospital standard practice. Number of participants with coronary spasm during ablation will be reported. |
Up to Day 365
|
|
VARIPURE Sub-Study: Number of Participants With Vagal Response During Ablation
Tidsramme: Up to Day 365
|
Ablation procedures using the varipulse medical device will be performed according to the hospital standard practice. Number of participants with vagal response during ablation will be reported. |
Up to Day 365
|
|
VARIPURE Sub-Study: Number of Participants With Acute Kidney Failure Post Ablation
Tidsramme: Up to Day 365
|
Ablation procedures using the varipulse medical device will be performed according to the hospital standard practice. Number of participants with acute kidney failure post ablation will be reported. |
Up to Day 365
|
|
DUACURE Sub-Study: Number of Participants With Coronary Spasm During Ablation
Tidsramme: Up to Day 365
|
Ablation procedures using the duacure medical device will be performed according to the hospital standard practice. Number of participants with coronary spasm during ablation will be reported. |
Up to Day 365
|
|
DUACURE Sub-Study: Number of Participants With Vagal Response During Ablation
Tidsramme: Up to Day 365
|
Ablation procedures using the duacure medical device will be performed according to the hospital standard practice. Number of participants with vagal response during ablation will be reported. |
Up to Day 365
|
|
DUACURE Sub-Study: Number of Participants With Acute Kidney Failure Post Ablation
Tidsramme: Up to Day 365
|
Ablation procedures using the duacure medical device will be performed according to the hospital standard practice. Number of participants with acute kidney failure post ablation will be reported. |
Up to Day 365
|
Samarbeidspartnere og etterforskere
Sponsor
Sponsor
Etterforskere
Etterforskere
- Studieleder: Biosense Webster, Inc. Clinical Trial, Biosense Webster, Inc.
Publikasjoner og nyttige lenker
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Studiestart
Primær fullføring (Antatt)
Primær fullføring
Studiet fullført (Antatt)
Studiet fullført
Datoer for studieregistrering
Først innsendt
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Først lagt ut
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Sist oppdatering lagt ut
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
Andre studie-ID-numre
- BWI_2019_05
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
The data sharing policy of Johnson & Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu.
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .